Adaptive Biotechnologies Corporation ADPT R2K
Healthcare · Diagnostics & Research · United States
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
READ MORE ›$15.15
+59.14% 1Y
Market & Price
Market Cap
$2.42B
Current Price
$15.15
High / Low (52W)
$20.46 / $9.52
Beta
2.16
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.35
Price to Book
11.18
P/S
8.21
EV/EBITDA
-81.33
Dividend Yield
-
Profitability & Returns
ROCE
-11.28%
ROE
-23.96%
ROA
-5.74%
Profit Margin
-16.82%
Op Margin
-27.10%
EPS (Latest Qtr)
$-0.13
EPS (TTM)
$-0.32
Balance Sheet & Liquidity
Debt/Equity
0.93
Quick Ratio
3.08
Current Ratio
3.35
Debt
$208.18M
Total Assets
$512.74M
Current Assets
$300.19M
Working Capital
$210.27M
Ownership
Promoter Holding
1.84%
Chg in Prom Hold
-
FII / Inst Holding
96.47%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$2.42B
Total Revenue (TTM)
$295.41M
EBITDA
$-29.79M
Free Cash Flow
$16.10M
Operating Cash Flow
$-27.04M
Shares Outstanding
160.04M
Gross Margin
43.71%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
14.34%
Profit 5Y
23.43%
Revenue (YoY)
35.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 14.3% over 5 years.
- Profit CAGR of 23.4% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 25.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADPT Adaptive Biotechnologies Corporation R2K | 15.15 | - | $2.42B | - | -11.28% | -23.96% | 14.34% | 23.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.57M | 17.19M | 12.67M | 22.14M | 26.06M | 20.91M | 20.99M | 26.30M | 38.44M | 38.51M | 39.47M | 38.62M | 43.66M | 47.83M | 37.65M | 48.93M | 37.92M | 41.87M | 43.19M | - | - | 52.44M | 58.88M | 93.97M | 71.68M | 70.87M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.98M | 18.00M | 18.16M | 18.22M | 18.71M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.46M | 40.88M | 75.82M | 53.46M | 52.17M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.07M | 65.92M | 65.53M | 66.23M | 71.37M |
| Operating Income | -13.31M | -9.16M | -20.05M | -16.11M | -18.05M | -34.62M | -36.91M | -37.05M | -41.28M | -49.77M | -56.33M | -63.07M | -52.50M | -45.43M | -57.19M | -47.82M | -50.96M | -48.76M | -47.32M | - | - | -29.60M | -25.04M | 10.29M | -12.77M | -19.21M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.19M | -18.14M | 16.92M | -6.43M | -13.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.90M | 2.95M | 2.97M | 2.95M | 2.89M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.83M | -25.59M | 9.54M | -13.58M | -20.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.49M | -8.29M | -18.39M | -15.66M | -13.95M | -31.40M | -33.53M | -36.72M | -40.64M | -49.30M | -55.90M | -62.74M | -52.05M | -45.28M | -57.70M | -47.81M | -50.30M | -47.51M | -46.22M | - | - | -29.85M | -25.61M | 9.55M | -13.58M | -20.03M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.35 | -0.40 | -0.44 | -0.37 | -0.32 | -0.40 | -0.33 | -0.35 | -0.33 | -0.31 | - | - | -0.20 | -0.17 | 0.06 | -0.09 | -0.13 |
| R&D Expense | 9.45M | 9.78M | 12.48M | 16.53M | 20.51M | 23.93M | 25.99M | 30.31M | 33.77M | 37.80M | 36.07M | 37.84M | 37.04M | 35.66M | 32.60M | 32.24M | 28.53M | 30.25M | 25.35M | 24.16M | - | 24.20M | 24.13M | 23.67M | - | 23.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.45M | 55.66M | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | - | - | - | - | - | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | - | - | - | - | - | 127.40M | 94.72M | 106.88M | 205.62M |
| Operating Expenses | - | - | - | - | - | 327.58M | 296.33M | 262.22M | 262.74M |
| Operating Income | -44.48M | -49.76M | -78.39M | -152.82M | -208.97M | -200.19M | -201.61M | -155.34M | -57.12M |
| EBITDA | - | - | - | - | - | -175.21M | -189.27M | -128.76M | -29.85M |
| Interest Expense | - | - | - | - | - | 4.24M | 13.80M | 11.58M | 11.78M |
| Pretax Income | - | - | - | - | - | -200.37M | -225.30M | -159.59M | -59.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.28M | -200.19M | -225.25M | -159.49M | -59.50M |
| Diluted EPS | - | - | - | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 |
| R&D Expense | 32.00M | 39.16M | 70.70M | 116.07M | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
Compounded Sales Growth
| 5 Years: | 14.34% |
| 1 Year: | 35.10% |
Compounded Profit Growth
| 5 Years: | 23.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +59.14% |
| 6 Months: | -25.44% |
| 3 Months: | -5.43% |
| 1 Month: | +11.97% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 332.69M | 912.30M | 1.12B | - | 856.62M | 661.13M | 539.38M | 512.74M |
| Current Assets | - | - | - | - | - | - | 562.15M | 410.19M | 283.75M | 300.19M |
| Cash & Equivalents | - | - | 55.03M | 96.58M | 123.44M | - | 90.03M | 65.06M | 47.92M | 70.50M |
| Inventory | - | - | - | - | - | - | 14.45M | 14.45M | 8.44M | 9.82M |
| Receivables | - | - | - | - | - | - | 40.06M | 37.97M | 41.73M | 50.37M |
| Total Liabilities | - | - | 29.94M | 341.26M | 373.15M | - | 392.52M | 352.86M | 336.89M | 287.74M |
| Current Liabilities | - | - | 22.80M | 78.31M | 105.20M | - | 109.79M | 88.02M | 98.05M | 89.92M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 108.00M | 98.77M | 89.39M | 79.15M |
| Total Equity | -189.73M | -224.62M | -258.11M | 571.04M | 743.27M | - | 464.17M | 308.40M | 202.71M | 218.79M |
| Shares Outstanding | - | - | - | - | - | - | 143.11M | 145.08M | 147.77M | 153.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -34.86M | -32.26M | 205.40M | -149.68M | - | -183.94M | -156.32M | -95.21M | -45.99M |
| Investing Cash Flow | 36.43M | 736.00K | -481.70M | -117.04M | - | 2.90M | 129.65M | 77.79M | 37.95M |
| Financing Cash Flow | 50.03M | 1.25M | 319.92M | 293.59M | - | 132.26M | 2.25M | 241.00K | 30.40M |
| Capital Expenditure | -2.42M | -6.30M | -11.20M | -18.80M | - | -16.35M | -10.70M | -3.66M | -2.96M |
| Free Cash Flow | -37.28M | -38.56M | 194.20M | -168.49M | - | -200.29M | -167.02M | -98.88M | -48.95M |
| Net Change in Cash | - | - | - | - | - | -48.77M | -24.43M | -17.18M | 22.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 68.7% | 55.6% | 59.7% | 74.2% |
| Operating Margin % | -115.7% | -89.4% | -92.1% | -155.3% | -135.4% | -108.0% | -118.4% | -86.8% | -20.6% |
| Net Margin % | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| ROE % | 19.1% | 18.0% | -12.0% | -19.7% | - | -43.1% | -73.0% | -78.7% | -27.2% |
| ROCE % | - | -16.1% | -9.4% | -15.1% | - | -26.8% | -35.2% | -35.2% | -13.5% |
Shareholding Pattern
Insiders
1.84%
Institutions
96.47%
Public Float
98.28%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Viking Global Investors, L.P. | 18.74% | 29.99M | $454.40M |
| 2 | Blackrock Inc. | 8.31% | 13.30M | $201.54M |
| 3 | Vanguard Capital Management LLC | 3.81% | 6.09M | $92.33M |
| 4 | Westfield Capital Management Co LP | 3.40% | 5.44M | $82.37M |
| 5 | Vanguard Portfolio Management LLC | 2.81% | 4.49M | $68.05M |
| 6 | Invesco Ltd. | 2.78% | 4.45M | $67.42M |
| 7 | Wellington Management Group, LLP | 2.41% | 3.86M | $58.44M |
| 8 | Geode Capital Management, LLC | 2.27% | 3.64M | $55.09M |
| 9 | Lord, Abbett & Co. LLC | 2.21% | 3.54M | $53.57M |
| 10 | Goldman Sachs Group Inc | 2.03% | 3.24M | $49.12M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADPT
No recent headlines available.